PDK inhibitors

PDK1 (Phosphoinositide-dependent kinase-1) also known as PDPK1 (3-phosphoinositide dependent protein kinase-1) is a serine/threonine protein kinase, which functions as a master kinase to phosphorylate and activate a subgroup of the AGC family kinases such as PKB/Akt, PKC, S6K, SGK, and RSK, thus, playing a pivotal role in the PI3K/Akt signaling pathway.

아이소폼 선택적 제품

Cat.No. 제품명 정보 제품 사용 인용 제품 검증
S1274 BX-795 BX-795는 6 nM의 IC50을 갖는 강력하고 특이적인 PDPK1 억제제로, 무세포 분석에서 PKA 및 PKC보다 각각 140배 및 1600배 더 높은 PDK1 선택성을 보입니다. 한편, GSK3β와 비교했을 때 PDK1에 대해 100배 이상의 선택성이 관찰되었습니다. BX-795는 ULK1을 억제하여 Autophagy를 조절합니다. 또한 BX-795는 강력한 TBK1 억제제로서, 각각 6 nM 및 41 nM의 IC50 값으로 TBK1 및 IKKε를 모두 차단합니다.
Cancer Res, 2025, 10.1158/0008-5472.CAN-25-1791
Cell Rep, 2025, 44(7):115972
EMBO J, 2024, 10.1038/s44318-024-00244-9
Verified customer review of BX-795
S0983 JX06 JX06은 세포 내 PDK1의 선택적 공유 결합 억제제입니다. 이 화합물은 PDK1, PDK2 및 PDK3을 각각 IC50 0.049 μM, 0.101 μM, 0.313 μM의 농도 의존적으로 억제합니다.
Biochem Biophys Res Commun, 2021, 587:153-159
S8615 Sodium Dichloroacetate (DCA) Sodium Dichloroacetate (DCA)는 PDK2 및 PDK4에 대해 각각 183 및 80 μM의 IC50 값을 갖는 PDK의 특이적 억제제로, NKCC 및 미토콘드리아 칼륨 이온 채널 축을 탈억제하는 것으로 밝혀졌습니다. Sodium Dichloroacetate는 ROS 생성을 증가시키고 암세포에서 Apoptosis related를 유발하며 종양 성장을 억제합니다.
bioRxiv, 2025, 2025.04.03.647023
bioRxiv, 2025, 2025.08.24.671623
bioRxiv, 2025, 2023.08.11.552890
S2949 KPLH1130 KPLH1130은 PDK의 특정 억제제로, 대식세포 분극화를 차단하고 전염증성 반응을 완화합니다.

PDK1 protein is composed of two well-characterized functional domains: (1) the N-terminal serine/threonine kinase domain of the AGC family, and (2) the C-terminal Pleckstrin homology (PH) domain that interacts with high affinity with both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 as well as other phosphoinositides such as PtdIns(4,5)P2. PDK1 is ubiquitously expressed and constitutively active in mammalian cells. In addition to being able to constitutively phosphorylate substrates, PDK1 also works in an inducible manner in response to specific stimuli. Without stimuli, the catalytic activity of PDK1 is kept under control by limiting its access to targets, whereas upon stimulation, the different PDK1 substrates are converted into forms that can be recognized, phosphorylated and activated by PDK1. PDK1 regulates as much as 23 growth-factor-stimulated AGC kinases, containing protein kinase B (PKB/Akt) isoforms, p70 ribosomal protein S6 kinase (S6K) isoforms, p90 ribosomal protein S6 kinases (RSK), serum- and glucocorticoid-induced protein kinase (SGK) isoforms, and several protein kinase C (PKC) isoforms, by phosphorylating at the serine/threonine residues in their T-loop. [1]

The autophosphorylation of PDK1 at Ser241 in the T-loop or activation loop contributes to the catalytic activity of PDK1 upon substrate binding, and several other phosphorylation sites have also been proposed to contribute to the regulation of PDK1 activity. Upon growth factor stimulation and PtdIns(3,4,5)P3 production, both PKB/Akt and PDK1 translocate to the plasma membrane via the specific interaction of their PH domains with newly generated PtdIns(3,4,5)P3, where PDK1 could then readily phosphorylate and activate PKB/Akt, allowing PKB/Akt to phosphorylate downstream targets such as Foxo1. The mTORC1 or mTORC2 mediated phosphorylation of the hydrophobic motif of AGC kinases is essential for PDK1-mediated activation. This is achieved by creating a docking site for the binding of PDK1 to facilitate the phosphorylation of the kinases at its T-loop by PDK1. Moreover, the interaction of the hydrophobic motif binding pocket (PIF pocket) of PDK1 with the phosphorylated hydrophobic motif in the substrate induces the allosteric activation of PDK1. [1]

Therefore, through targeting a particular set of these AGC kinases, PDK1 play a critical role in regulating a wide variety of physiological processes including cell growth, proliferation, survival, development, and metabolism. PDK1 knockout mice die during early embryonic development, and the PDK1 dominant negative mutants knock-in mice are also shown to be embryonically lethal. A series of tissue-specific conditional knockout mice lacking PDK1 also confirm both the implication of PDK1 in mediating metabolic responses to insulin as well as in promoting cell viability, which proposes that selective activation of PDK1 might be a good strategy for the treatment of diabetes. However, PDK1 overexpression and amplification of the PDK1 gene are common occurrences in breast cancer and acute myeloid leukaemia. PDK1 also displays an epistatic relationship with the lipid phosphatase PTEN in the migration and malignant transformation of lymphocytes and in regulating nervous system development. Moreover, PTEN heterozygous mice expressing reduced levels of PDK1 are markedly protected from developing a wide range of tumors, indicating that PDK1 is a key effector in mediating tumorigenesis resulting from loss of PTEN and further validating PDK1 as a valuable anticancer target for the development of specific inhibitors. [1]